BioSpace News Archive

Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2022.

Nykode Therapeutics ASA today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 8:00 a.m. ET / 2:00 p.m. CET.

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

GN Hearing, the global leader in hearing aid innovation, announces the expansion of the popular ReSound OMNIA family, providing more options to address the biggest unmet need for people with hearing loss: hearing speech in noisy environments.

Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2023, which ended December 31, 2022, are available on its Investor Relations website.

Partnership with renowned doctor will leverage MediSure Labs diagnostics facility commencing as a Site Management Organization in Dallas to serve clinical trials market.

AC Immune SA (NASDAQ: ACIU) today announced prestigious new grants from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43).

HOOKIPA Pharma Inc. today announced that the company will participate in the virtual SVB Securities Global Biopharma Conference, February 14 - 16, 2023.

Genenta Science has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta’s ongoing clinical programs.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th -16th , 2023.